Business context and reporting period
Champions Oncology, Inc. filed this Form 10-K for the fiscal year ended April 30, 2017, with fiscal 2016 comparatives. The request metadata says “2016 Q4,” but the filing covers the full fiscal year ended April 30, 2017, not a standalone quarter. The company sells TumorGraft-based oncology research services: Translational Oncology Solutions (TOS) for pharmaceutical and biotechnology customers, and Personalized Oncology Solutions (POS) for physicians and patients.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $15.411 million | $11.182 million |
| Operating loss | $6.809 million | $10.316 million |
| Net loss | $6.884 million | $10.446 million |
| Basic and diluted loss per share | $0.64 | $1.20 |
| Operating cash used | $2.840 million | $6.408 million |
| Investing cash used | $0.766 million | $0.322 million |
| Financing cash provided | $4.316 million | $0.042 million used |
TOS revenue was $13.691 million, up 48.7%; POS revenue was $1.720 million, down 12.8%. TOS gross margin improved to 39.6% from 28.5%; POS gross margin improved to 16.7% from negative 6.6%. Overall operating margin was approximately negative 44.2% (operating loss divided by revenue), versus negative 92.3% in FY2016. No net-profit or cash-flow positive period was reported.
At April 30, 2017, cash and cash equivalents were $3.295 million, current assets $5.869 million, current liabilities $7.447 million, and working capital was negative $1.6 million. Deferred revenue was $4.910 million. Total assets were $8.011 million, total liabilities $7.611 million, and stockholders’ equity $0.400 million. Cash was reported at $1.0 million as of July 15, 2017. The company said available cash was expected to fund operations through at least August 2018, but cautioned that additional capital might be needed and could not be assured on acceptable terms.
There was no reported off-balance-sheet debt. The company had a $63,000 capital-lease obligation at year-end ($25,000 current and $38,000 long-term). Operating-lease commitments totaled approximately $7.214 million, including the long-term Rockville laboratory lease.
Material changes versus the prior comparable period
- Revenue rose 37.8%, driven by higher TOS study bookings, including larger studies.
- Net loss narrowed by about $3.562 million, while operating expenses increased 3.4% to $22.220 million. Revenue growth and cost management improved operating results.
- Operating cash use fell by $3.568 million, attributed to revenue growth and management of fixed and laboratory costs.
- POS activity declined: implants fell 47.9% to 74, and completed patient panels fell 12.5% to 42. Management said POS would not be the focus of future growth.
- On June 15, 2016, the company issued 2,258,749 shares in a public offering and partial over-allotment, raising approximately $4.340 million net. Share count and paid-in capital increased.
Outlook, commentary, risks and unusual items
- Management’s strategy is to expand TOS by growing the TumorBank, developing ImmunoGrafts for immuno-oncology research, and increasing study scale. The filing gives no quantified revenue or earnings guidance.
- The company reported continuing expected operating losses and a $69.350 million accumulated deficit. Its stated cash runway depends on its estimates; subsequent cash of $1.0 million at July 15, 2017 is a significant liquidity consideration.
- Nasdaq notified the company on April 24, 2017 that it did not meet the $35 million market-value-of-listed-securities requirement. The stated compliance deadline was October 23, 2017; the filing offered no assurance of compliance.
- Key business risks include dependence on pharmaceutical and biotech study demand and possible study cancellations, customer concentration, competition, limited sales capacity, lack of patent protection for the TumorGraft platform, and potential FDA oversight of laboratory-developed tests. One TOS customer represented 21.3% of FY2017 revenue; two customers represented 55.0% of year-end receivables combined.
- The company depends on laboratory and live-mouse operations; facility damage, transition disruptions, or a mouse-colony health crisis could harm its business. The Rockville laboratory was scheduled to commence operations in August 2017.
- Management reported effective disclosure controls and effective internal control over financial reporting as of April 30, 2017. The financial statements received an unqualified audit opinion; the auditor was not engaged to audit internal control effectiveness.
- Unusual compensation expense included a $612,534 option-extension modification charge and $373,069 recognized from an option exchange modification during FY2017. The company also disclosed possible limits on use of tax-loss carryforwards under Section 382; an ownership change had not been calculated.
Most important facts for investors to verify
- Current cash, burn rate, financing needs, and whether the stated runway through August 2018 was achieved.
- Progress against Nasdaq’s market-value listing requirement and the resulting status of the common stock’s listing.
- Whether TOS growth and margin gains continued, and the extent of customer concentration, cancellations, and deferred-revenue conversion.
- Execution and costs of the Rockville laboratory transition and the long-term lease commitments.
- Regulatory developments affecting laboratory-developed tests, and any determination of Section 382 limits on tax attributes.
- Potential dilution from outstanding options and warrants: 4,312,988 potential shares were outstanding at year-end.